Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
Same Quarter, Two Different Worlds: Kossan vs. Hartalega
Both Kossan and Hartalega just reported results for the exact same calendar quarter (July–Sept 2026), and the contrast shows why business model and execution matter so much in a tough glove market:
Kossan (3Q26) — Firing on All Cylinders:
• Net Profit: Jumped +35.6% QoQ to RM87.4M (9M26 EPS hit 7.58 sen, nearly double last year).
• Margins: All 3 divisions (Gloves, Technical Rubber, Clean-Room) delivered 16%–17%+ PBT margins.
• Cash & Dividend: Sitting on ~RM1.58B net cash (RM0.63/share—over half its RM1.16 share price!) and declared a 2.5 sen dividend.
Hartalega (2QFY27) — Caught in the Squeeze:
• Net Profit: Dropped -53.2% QoQ to RM32.8M (from RM70.0M in 1Q).
• Headwinds: Hurt by high-cost nitrile inventory lag and vessel shortages capping on-time shipments below 70%.
• Cash & Dividend: Still holds a solid RM1.12B net cash (RM0.33/share), but skipped its 2Q dividend.
Why the Gap?
1. Diversification: Kossan’s Technical Rubber and Clean-Room units brought in ~RM15M PBT this quarter—shielded from generic medical glove price wars.
2. Product Mix vs. Scale: Kossan focuses on higher-margin specialty/customized gloves, while Harta is a pure-play commodity nitrile giant that feels sharper swings when freight or feedstock costs misalign.
My Takeaway
Harta remains a cash-rich survivor for a 2027 automation turnaround, but on pure numbers right now, Kossan is executing better, paying steady dividends, and trading at less than half Harta’s ex-cash P/E.
The core issue: The extreme divergence in target prices (TA: 1.13 vs. HLG: 0.80) is not a math error. It is a fundamental disagreement on one question: Is the recent ASP (Average Selling Price) increase structural or temporary?
1. The "Wait and See" Thesis (For the Cautious)
• Don't anchor to a single target price. TA is betting on long-term cost leadership (new tech), while HLG is betting on a temporary supply shortage fading. The 0.80 to 1.13 range is the market's way of saying "we don't know yet."
• The market consensus is "Hold" for a reason. With the average target around 1.14 and 12 out of 17 analysts on "Hold," the smart money is waiting for the next quarterly report.
2. The "Shorty / Bear" Thesis (For the Aggressive)
• The bear case is currently winning on the charts. HLG's 0.80 target is supported by the reality of falling Brent crude prices (which usually lowers input costs but can also trigger ASP price wars) and rising gas/minimum wage costs.
• Watch the RM1.00 psychological floor. The stock is already at 1.02. If it breaks RM1.00 with high volume, the "bear thesis" (HLG/RHB) is proven right, and the next leg down could be violent.
The Golden Rule
Trade the reaction, not the prediction.
Instead of arguing about who is right (TA or HLG), watch the data. The only thing that matters now is the next quarterly earnings release. If management guides for lower ASPs, HLG's 0.80 becomes the base case. If management shows resilient margins, TA's 1.13 comes back into play.
Harta is dropping 9% to RM1.06 is a classic "Retail Panic vs. Institutional Reality" disconnect. Here is my Munger/Buffett breakdown of why the market is acting irrationally.
Why the Market is Irrational (The "Headline Trap")
The retail investors (and algorithmic trading bots) are selling because they are looking at the headline numbers:
• "Q2 Profit dropped 53%!"
• "Operating margin collapsed from 13.2% to 6.3%!"
They are comparing Q2 to Q1. They are saying: "Harta is dying. Get out."
But the truth:
This was the Base Case (even slightly Bullish). We predicted Q2 profit would be RM20-25M. It came in at RM32.8M. The company is more resilient than the analysts feared. The 9% drop is purely a panic reaction to the word "drop," not a reaction to the actual fundamentals.
The Math the Market is Missing:
Let's look at the 1H Cumulative (First Half) numbers from the QR available:
The stock is trading at RM1.06. That is a ~19% discount to its Net Asset Value (NAV). The market is literally pricing Harta as if it is going to go bankrupt, even though it just made RM 102 Million in six months and has RM 1.19 Billion in cash.
The Munger View: "When a company is trading below its liquidation value and has zero debt, the downside is limited. The market is selling because it is short-sighted."
What Happens Next? (The Q3 Recovery)
The Q2 result was the "Trough." It was the quarter where the expensive inventory (RM465M) hit the P&L.
By Q3 (Oct-Dec), the fundamentals change completely:
1. The expensive inventory is burned off.
2. They are now using the new cheap NBR (US$900).
3. The ASP is stabilizing around US$19-20.
4. Plant 3 is fully online.
The Math for Q3: Even if ASP stays low, using cheap NBR instead of expensive NBR will add ~RM 15-20 Million directly to the bottom line. Q3 profit should recover to RM 40M - RM 50M.
When the market sees that Q3 profit is higher than Q2, they will realize the Q2 drop was a temporary accounting quirk. The stock will re-rate back up.
Good:
1H margin 2.0%→9.6% | net cash ~RM1.19bn | NAV RM1.31 | div 1.80sen paid | Plant 9 live, 5 Plant 3 lines recommissioned | US tariff tailwind
Bad:
Revenue up but profit halved (negative op leverage) | ASPs dropped late Q2, costs not fully passed through | FX drag | oversupply caps pricing | tax flattered by allowances | RM101.4m IRB contingent liability
Worst:
ASP war as China supply redirects | Middle East re-escalation | tariff edge erodes | MYR strength + tax normalisation + ASP decline = triple hit | Plant 3/4 execution risk
Bottom line: Base case validated by 1H, but Q2 is a clear deceleration — Q1 pricing spike already reversed. No solvency risk, but earnings volatility high. Watch Q3 QoQ trend.
• Institutional Benchmark: Major institutional research (such as CIMB Securities) utilizes a COE (r) of 9.3% and a terminal growth rate (g) of 3.0% for RCE Capital, yielding a target justified P/B multiple of 1.89x.
The Bear Case: "The Inventory Trap" (RM 10M – RM 15M)
The Scenario: Hartalega is forced to use the US18-19 (worse than the expected US$21-22) because Chinese competitors aggressively dump gloves into Europe and Asia to survive.
• The Math: Revenue falls to ~RM 450M. Because they are selling cheap gloves made from expensive NBR, the Gross Margin gets crushed to ~3% - 4%.
The Base Case: "The Cost Mismatch Normalization" (RM 20M – RM 25M)
The Scenario: This is the most probable path. The ASP averages US900-1,000).
• The Math: Revenue is ~RM 480M. Gross Margin recovers slightly to ~6% - 7% because the last month of the quarter (September) shows the new, healthier margins.
The Bull Case: "The Quick Burn" (RM 35M – RM 40M)
The Scenario: Hartalega's management was smarter than we thought. They had long-term contracts that locked in lower NBR prices, or they burned through the expensive inventory very quickly (by mid-July). The ASP holds up at US$22 because the Middle East conflict flares up again.
• The Math: Revenue is ~RM 500M. COGS drops rapidly as they switch to the new US$900 NBR. Gross Margin stays healthy at ~9% - 10%.
The Glove Industry: A Roller Coaster We've All Ridden
I've been watching this sector for years, and what a ride it's been.
Phase 1: The Demand Shock (2020–2021)
COVID hit. Gloves became gold. ASPs skyrocketed, plant utilisation hit 100%, and every player was printing money. Hartalega's FY21 net profit hit RM2.4b, FY22 RM2.6b. Dividends hit 50–57 sen. Everyone thought it would last forever.
Phase 2: The Supply Flood (2022–2023)
It didn't. Everyone expanded. China's Intco and Bluesail ramped up aggressively, dumping supply into the market. ASPs collapsed. Hartalega swung to a RM218m net loss in FY23. Top Glove bled for two years. The red ocean was brutal — overcapacity, price wars, and margin destruction.
Phase 3: The Slow Grind Back (2024–2026)
The survivors didn't sit still. Malaysian players — Top Glove, Hartalega, Kossan — went into overdrive on manpower, process, plant, and equipment optimisation. Automation, workforce consolidation, cost-per-unit reduction. They couldn't control ASPs, so they controlled what they could.
Then came the tailwinds:
· Raw material shortages (NBR supply tightness)
· Geopolitical instability (Middle East tensions → oil spike → cost pass-through)
· Improved pricing discipline among Chinese makers
· Gradual demand recovery
Phase 4: Where Are We Now? (2026–2027)
The industry is normalising — but not to the astronomical profits of 2021. To something more... decent. Hartalega's FY27 forecasts show ~RM70m net profit. Top Glove's FY27F ranges from RM218m to RM525m depending on who you ask (yes, the analyst spread is that wide).
This is the new reality: a fragile oligopoly, not a gold rush.
The Key Insight:
This industry will kill everyone in a pure red ocean. But if it consolidates into a rational oligopoly — where the top players compete on cost, not price — everyone survives. Not with 50% margins, but with decent, sustainable profits.
And then you wait.
Because the next huge demand surge — whether from a new health hazard, a pandemic, or a structural shift in global hygiene standards — will come. And when it does, the players who survived the downcycle, optimised their cost base, and kept their balance sheets clean will be the ones who ride it hardest.
The Lesson:
Cyclical industries are not about timing the top. They're about surviving the bottom. The companies that cut fat, invested in efficiency, and didn't blow up their balance sheets during the boom are the ones still standing.
Top Glove and Hartalega are still standing. That's not nothing.
---
Not investment advice. DYODD. I'm just sharing my observations from watching this sector go through its full cycle.
Three concrete actions management should prioritize, ranked by potential impact:
1. Execute the Fleet Renewal with Precision: The market doesn't reward potential; it rewards execution. The new 60T AHTS vessels, scheduled for delivery in 2028, need to be delivered on time and on budget. These modern, more fuel-efficient vessels could significantly improve operational margins and contract rates, directly boosting future earnings.
2. Demonstrate Consistent Profitability: Investors need proof that the company can make money in any market, not just during oil price spikes. A key metric to watch is the Return on Equity (ROE). A sustained improvement in ROE, driven by higher vessel utilization and better cost management, would give investors a reason to buy, making the stock's low P/B ratio (0.4x) truly attractive.
3. Establish a Clear Capital Return Policy: A dividend is often a more credible signal of confidence than a buyback . The recent share capital reduction has cleared the path for future distributions . If Perdana can start paying a consistent, sustainable dividend, it would attract a whole new class of income-focused investors.
Six professionals, same facts, wildly different conclusions. This isn't a bug — it's the market's way of saying "we don't know."
Buffett and Munger don't read analyst reports for a reason: they're often backward-looking, constrained by career risk and can't replace primary research.
This is what you to do instead:
• Read the actual 4QFY26 financials and concall transcript
• Ask yourself: "Do I believe the ASP spike is durable? Can they pass through costs? Will China compete harder?"
• Your answer — not the analysts' — should drive your decision